BRPI0816904A2 - Formas sólida, amorfa e cristalina, composição farmacêutica, e, método para tratar uma doença - Google Patents

Formas sólida, amorfa e cristalina, composição farmacêutica, e, método para tratar uma doença

Info

Publication number: BRPI0816904A2
Authority: BR; Brazil
Prior art keywords: amorphous; disease; treating; solid; pharmaceutical composition
Prior art date: 2007-09-19

Application number

Other languages

English (en)

Inventor

Shripad Bhagwat

Wei Lai

Stephan D Parant

Melanie J Roe

Alan Schwartz

Valeriya N Smolenskaya

Original Assignee

Ambit Biosciences Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-19

Filing date

2008-09-19

Publication date

2015-03-17

2008-09-19 Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp

2015-03-17 Publication of BRPI0816904A2 publication Critical patent/BRPI0816904A2/pt

2021-08-10 Publication of BRPI0816904B1 publication Critical patent/BRPI0816904B1/pt

2021-12-07 Publication of BRPI0816904B8 publication Critical patent/BRPI0816904B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Neurology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)

BRPI0816904A 2007-09-19 2008-09-19 Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida BRPI0816904B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US99463507P	2007-09-19	2007-09-19
US60/994635		2007-09-19
PCT/US2008/010884 WO2009038757A2 (en)	2007-09-19	2008-09-19	Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Publications (3)

Publication Number	Publication Date
BRPI0816904A2 true BRPI0816904A2 (pt)	2015-03-17
BRPI0816904B1 BRPI0816904B1 (pt)	2021-08-10
BRPI0816904B8 BRPI0816904B8 (pt)	2021-12-07

Family

ID=40468693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816904A BRPI0816904B8 (pt)	2007-09-19	2008-09-19	Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida

Country Status (20)

Country	Link
US (2)	US8883783B2 (pt)
EP (1)	EP2201018B1 (pt)
JP (1)	JP5462168B2 (pt)
KR (2)	KR101572701B1 (pt)
CN (1)	CN101868465B (pt)
AR (1)	AR068528A1 (pt)
AU (1)	AU2008302744B2 (pt)
BR (1)	BRPI0816904B8 (pt)
CA (1)	CA2696776C (pt)
CY (1)	CY1117583T1 (pt)
DK (1)	DK2201018T3 (pt)
ES (1)	ES2573292T3 (pt)
HR (1)	HRP20160520T1 (pt)
HU (1)	HUE027982T2 (pt)
IL (1)	IL203926A (pt)
MX (1)	MX2010002295A (pt)
PL (1)	PL2201018T3 (pt)
SI (1)	SI2201018T1 (pt)
TW (1)	TWI437988B (pt)
WO (1)	WO2009038757A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101549364B1 (ko)	2006-03-17	2015-09-01	암비트 바이오사이언시즈 코포레이션	질환 치료용 이미다졸로티아졸 화합물
US8883783B2 (en)	2007-09-19	2014-11-11	Ambit Biosciences Corporation	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
US7968543B2 (en) *	2007-11-08	2011-06-28	Ambit Biosciences Corporation	Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
CA2755976C (en)	2009-03-23	2020-04-07	Ambit Biosciences Corporation	Methods of treatment using combination therapy
SMT202000092T1 (it)	2009-05-14	2020-05-08	Ambit Biosciences Corp	Formulazione essiccata a spruzzo o liofilizzata di ac220
JP5762426B2 (ja) *	2009-11-05	2015-08-12	アムビトビオスシエンセスコルポラチオン	イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール誘導体の調製方法
WO2011056764A1 (en)	2009-11-05	2011-05-12	Ambit Biosciences Corp.	Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
CN103172648B (zh) *	2011-12-20	2016-05-25	上海迪诺医药科技有限公司	三杂环衍生物、制备方法及应用
JP6116847B2 (ja)	2012-10-01	2017-04-19	アムビトバイオサイエンシスコーポレーションＡｍｂｉｔＢｉｏｓｃｉｅｎｃｅｓＣｏｒｐｏｒａｔｉｏｎ	シクロデキストリンとの混合体を含有する錠剤
CN104513257B (zh) *	2013-09-26	2017-02-15	广东东阳光药业有限公司	取代脲衍生物及其在药物中的应用
KR102595395B1 (ko)	2015-02-20	2023-10-27	다이이찌 산쿄 가부시키가이샤	암의 병용 치료법
AU2018299536B2 (en) *	2017-07-13	2022-06-02	Sunshine Lake Pharma Co., Ltd.	Salt of substituted urea derivative and use thereof in medicine
CN111065270A (zh) *	2017-07-18	2020-04-24	阿格里麦蒂斯有限责任公司	L-草胺膦的生产方法
CN110763544A (zh) *	2019-09-20	2020-02-07	南京聚谱检测科技有限公司	一种激光剥蚀样品制靶用快干可精磨粘合剂
CN111413421A (zh) *	2020-02-20	2020-07-14	广东电科院能源技术有限责任公司	污泥燃烧后灰尘中氯离子含量的测试方法、控制方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL129432C (pt)	1964-02-29
NL129626C (pt)	1964-04-08
US3210370A (en)	1964-06-22	1965-10-05	Upjohn Co	Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr)	1979-08-21	1981-02-27	Yamanouchi Pharma Co Ltd	Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en)	1980-03-07	1982-10-19	Eastman Kodak Company	Indoline coupled isothiazole azo dyes
JPS56138196A (en)	1980-03-29	1981-10-28	Yamanouchi Pharmaceut Co Ltd	Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en)	1980-08-22	1982-03-06	Yamanouchi Pharmaceut Co Ltd	Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en)	1981-03-12	1982-09-14	Yamanouchi Pharmaceut Co Ltd	Imidazo(2,1-b)benzothiazole derivative
US4464384A (en)	1981-12-23	1984-08-07	Yamanouchi Pharmaceutical Co., Ltd.	2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
JPS58109491A (ja) *	1981-12-23	1983-06-29	Yamanouchi Pharmaceut Co Ltd	２−フエニルイミダゾ〃２，１−ｂ「あ」ベンゾチアゾ−ル誘導体
US5236952A (en)	1986-03-11	1993-08-17	Hoffmann-La Roche Inc.	Catechol derivatives
US4880824A (en)	1987-09-21	1989-11-14	Ortho Pharmaceutical Corporation	Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr)	1991-07-19	1993-01-20	Synthelabo	Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja)	1991-10-17	1993-04-30	Konica Corp	新規な写真用カプラー
DK0571253T3 (da)	1992-05-19	1999-07-19	Adir	Benzimidazolderivater med antidiabetisk og antiblodpladekoagulerende virkning
FR2699920B1 (fr)	1992-12-24	1995-02-10	Synthelabo	Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2700546B1 (fr)	1993-01-15	1995-02-17	Synthelabo	Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr)	1993-01-15	1994-07-20	Synthelabo	Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
JPH07291976A (ja)	1994-04-27	1995-11-07	Otsuka Pharmaceut Factory Inc	イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr)	1994-07-13	1996-08-09	Synthelabo	Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
CA2215197A1 (en)	1995-03-13	1996-09-19	Shigeyuki Tasaka	Imidazothiazole compound
WO1998006724A1 (en)	1996-08-09	1998-02-19	Yamanouchi Pharmaceutical Co., Ltd.	Metabotropic glutamate receptor agonists
US6127387A (en)	1996-12-10	2000-10-03	Thomas Jefferson University	Use of CD4-binding small molecules to inhibit immune responses
FR2759698B1 (fr)	1997-02-20	1999-03-19	Synthelabo	Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja)	1997-10-02	1999-04-20	Sumitomo Pharmaceut Co Ltd	Ｓｔａｔ６活性化阻害剤
EP1047418B1 (en)	1997-12-22	2005-07-27	Bayer Pharmaceuticals Corp.	Inhibition of raf kinase using substituted heterocyclic ureas
DE19805117A1 (de)	1998-02-09	1999-08-12	Bayer Ag	Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de)	1999-02-09	2000-08-10	Bayer Ag	Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja)	1999-08-05	2001-02-20	Yamanouchi Pharmaceut Co Ltd	三環式ヘテロアリール誘導体
DE19948434A1 (de)	1999-10-08	2001-06-07	Gruenenthal Gmbh	Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja)	1999-10-29	2001-07-17	Meiji Seika Kaisha Ltd	新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de)	2000-04-20	2002-01-10	Gruenenthal Gmbh	Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU7887501A (en)	2000-07-06	2002-01-21	Us Gov Health & Human Serv	Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en)	2000-08-11	2004-02-24	The Regents Of The University Of California	Inhibition of p53-induced stress response
US7601846B2 (en)	2001-06-26	2009-10-13	The Regents Of The University Of California	Compounds having activity as inhibitors of apoptosis
AU2002334969A1 (en)	2001-10-09	2003-04-22	Sylvie Barchechath	Use of stat-6 inhibitors as therapeutic agents
US20040127719A1 (en)	2002-03-08	2004-07-01	Kexin Yang	Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
TW200409746A (en) *	2002-07-26	2004-06-16	Theravance Inc	Crystalline β2 adrenergic receptor agonist
EP1565459A2 (en)	2002-11-25	2005-08-24	Pharmacia Corporation	Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
MXPA05006438A (es)	2002-12-18	2005-09-08	Mallinckrodt Inc	Derivados de acetamidas de heteroarilo.
KR100647583B1 (ko)	2003-10-07	2006-11-17	삼성에스디아이 주식회사	이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
CA2545711A1 (en)	2003-11-13	2005-06-02	Ambit Biosciences Corporation	Urea derivatives as kinase modulators
KR101549364B1 (ko) *	2006-03-17	2015-09-01	암비트 바이오사이언시즈 코포레이션	질환 치료용 이미다졸로티아졸 화합물
US8883783B2 (en)	2007-09-19	2014-11-11	Ambit Biosciences Corporation	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
US7968543B2 (en)	2007-11-08	2011-06-28	Ambit Biosciences Corporation	Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

2008
- 2008-09-19 US US12/233,906 patent/US8883783B2/en active Active
- 2008-09-19 JP JP2010525832A patent/JP5462168B2/ja active Active
- 2008-09-19 HU HUE08832577A patent/HUE027982T2/en unknown
- 2008-09-19 DK DK08832577.4T patent/DK2201018T3/en active
- 2008-09-19 KR KR1020107008302A patent/KR101572701B1/ko active Active
- 2008-09-19 AU AU2008302744A patent/AU2008302744B2/en active Active
- 2008-09-19 AR ARP080104110A patent/AR068528A1/es unknown
- 2008-09-19 CA CA2696776A patent/CA2696776C/en active Active
- 2008-09-19 MX MX2010002295A patent/MX2010002295A/es active IP Right Grant
- 2008-09-19 SI SI200831613A patent/SI2201018T1/sl unknown
- 2008-09-19 ES ES08832577.4T patent/ES2573292T3/es active Active
- 2008-09-19 WO PCT/US2008/010884 patent/WO2009038757A2/en not_active Ceased
- 2008-09-19 EP EP08832577.4A patent/EP2201018B1/en active Active
- 2008-09-19 BR BRPI0816904A patent/BRPI0816904B8/pt active IP Right Grant
- 2008-09-19 KR KR1020157023723A patent/KR20150104231A/ko not_active Ceased
- 2008-09-19 TW TW097136260A patent/TWI437988B/zh active
- 2008-09-19 HR HRP20160520TT patent/HRP20160520T1/hr unknown
- 2008-09-19 PL PL08832577.4T patent/PL2201018T3/pl unknown
- 2008-09-19 CN CN2008801167866A patent/CN101868465B/zh active Active
2010
- 2010-02-11 IL IL203926A patent/IL203926A/en active IP Right Grant
2014
- 2014-10-07 US US14/508,967 patent/US9585892B2/en active Active
2016
- 2016-05-24 CY CY20161100450T patent/CY1117583T1/el unknown

Also Published As

Publication number	Publication date
US9585892B2 (en)	2017-03-07
CY1117583T1 (el)	2017-04-26
HRP20160520T1 (hr)	2016-07-29
ES2573292T9 (es)	2016-07-08
CN101868465A (zh)	2010-10-20
MX2010002295A (es)	2010-03-22
EP2201018B1 (en)	2016-03-16
JP2010539237A (ja)	2010-12-16
AR068528A1 (es)	2009-11-18
AU2008302744A1 (en)	2009-03-26
CA2696776C (en)	2015-12-15
CN101868465B (zh)	2013-12-25
EP2201018A2 (en)	2010-06-30
JP5462168B2 (ja)	2014-04-02
BRPI0816904B8 (pt)	2021-12-07
KR101572701B1 (ko)	2015-11-27
DK2201018T3 (en)	2016-05-17
IL203926A (en)	2016-02-29
AU2008302744B2 (en)	2014-01-30
TWI437988B (zh)	2014-05-21
KR20100061734A (ko)	2010-06-08
TW200920360A (en)	2009-05-16
WO2009038757A3 (en)	2009-05-28
US20150238499A1 (en)	2015-08-27
CA2696776A1 (en)	2009-03-26
BRPI0816904B1 (pt)	2021-08-10
ES2573292T3 (es)	2016-06-07
WO2009038757A2 (en)	2009-03-26
KR20150104231A (ko)	2015-09-14
US20090131426A1 (en)	2009-05-21
PL2201018T3 (pl)	2016-11-30
US8883783B2 (en)	2014-11-11
SI2201018T1 (sl)	2016-09-30
HUE027982T2 (en)	2016-11-28

Publication	Publication Date	Title
BRPI0816904A2 (pt)	2015-03-17	Formas sólida, amorfa e cristalina, composição farmacêutica, e, método para tratar uma doença
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0814503A2 (pt)	2017-05-16	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0922566A2 (pt)	2017-03-28	polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0908092A2 (pt)	2015-08-25	Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0814688A2 (pt)	2017-06-06	composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica
BRPI0914918A2 (pt)	2015-10-20	forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0812847A2 (pt)	2014-12-09	Uretano acrilado, composição, e, método para reticular pelo menos parcialmente a composição
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0721121A2 (pt)	2014-03-04	Escova de dentes, e, método para fabricar uma escova de dentes
BRPI0817727A2 (pt)	2017-05-16	composição de graxa lubrificante, e, método para preparar uma composição de graxa
BRPI0912384A2 (pt)	2015-10-13	composição, e, método para preparar uma composição
BRPI0814163A2 (pt)	2015-01-20	Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0721502A2 (pt)	2015-03-31	Método para tratamento de uma formação fraturada
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0817923A2 (pt)	2015-04-07	Implemento para cuidado oral, e, método
BRPI0817917A2 (pt)	2015-04-07	Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI1007161A2 (pt)	2016-02-23	composição farmacêutica oral, e processo para preparar uma composição
BRPI0818430A2 (pt)	2014-10-07	Composição antiperspirante sólida e método para a produção da mesma
BRPI0810946A2 (pt)	2014-10-21	Método para tratamento de hérnia de disco
BRPI0814300A2 (pt)	2015-02-03	Composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI1007211A2 (pt)	2019-09-24	composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição.

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-08-11	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-03-09	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-06-22	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-08-10	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2021-12-07	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2640 DE 10/08/2021 QUANTO AO INVENTOR.